EZH2 and Familial prostate cancer: Indeed, ISO treatment in prostate cancer cells induces angiogenesis tube formation of SVEC4-10 endothelial cells, which is reversed either by treating prostate cancer cells with EZH2 inhibitor GSK126 or EPZ6438, or by adding TSP1 peptide to the conditioned medium of cancer cells (Fig. 9a).